Catalyst Pharmaceutical Partners shares owned by Principal Financial Group
Quarter-by-quarter ownership of Catalyst Pharmaceutical Partners (CPRX) shares owned by Principal Financial Group
from 13F filings
Historical chart of Principal Financial Group investment in Catalyst Pharmaceutical Partners
Tip: Access up to 7 years of quarterly data
All positions including Catalyst Pharmaceutical Partners held by Principal Financial Group consolidated in one spreadsheet with up to 7 years of data
Download as csv
Download as Excel
Quarterly reported holdings in Catalyst Pharmaceutical Partners by Principal Financial Group
| Quarter filed | Position value | Share count | Share price at filing |
|---|---|---|---|
| 2025-09-30 | $13M | 639k | 19.70 |
| 2025-06-30 | $14M | 624k | 21.70 |
| 2025-03-31 | $15M | 618k | 24.25 |
| 2024-12-31 | $13M | 601k | 20.87 |
| 2024-09-30 | $11M | 576k | 19.88 |
| 2024-06-30 | $9.9M | 639k | 15.49 |
| 2024-03-31 | $10M | 649k | 15.94 |
| 2023-12-31 | $9.7M | 578k | 16.81 |
| 2023-09-30 | $6.8M | 578k | 11.69 |
| 2023-06-30 | $7.8M | 581k | 13.44 |
| 2023-03-31 | $10M | 614k | 16.58 |
| 2022-12-31 | $12M | 632k | 18.60 |
| 2022-09-30 | $7.8M | 608k | 12.83 |
| 2022-06-30 | $512k | 73k | 7.02 |
| 2022-03-31 | $653k | 79k | 8.29 |
| 2021-12-31 | $803k | 119k | 6.77 |
| 2021-06-30 | $64k | 11k | 5.71 |
| 2021-03-31 | $95k | 21k | 4.59 |
| 2020-12-31 | $87k | 26k | 3.34 |
| 2020-09-30 | $107k | 36k | 2.96 |
| 2020-06-30 | $176k | 38k | 4.63 |
| 2020-03-31 | $106k | 28k | 3.84 |
| 2019-12-31 | $105k | 28k | 3.73 |
| 2019-09-30 | $158k | 30k | 5.30 |
| 2019-06-30 | $107k | 28k | 3.86 |
| 2019-03-31 | $66k | 13k | 5.08 |
| 2018-12-31 | $28k | 15k | 1.90 |
| 2018-09-30 | $69k | 18k | 3.75 |
| 2018-06-30 | $45k | 14k | 3.13 |
| 2017-12-31 | $44k | 11k | 3.92 |
| 2017-09-30 | $28k | 11k | 2.50 |
| 2017-06-30 | $36k | 13k | 2.75 |
| 2016-03-31 | $15k | 13k | 1.18 |
| 2015-12-31 | $31k | 13k | 2.43 |
| 2015-09-30 | $38k | 13k | 2.98 |
Top funds holding Catalyst Pharmaceutical Partners
View all funds holding Catalyst Pharmaceutical Partners